80 completed, 21 unknown, 5 terminated, 4 recruiting. 117 Phase 3, 15 Phase 2.
Follow Vaginal Diseases: new trials by email Literature Review of Vaginal Diseases trials Research Report on Vaginal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth Vaginal flora abnormalities screening and quantification using molecular biology technique, Azithromycin, Ceftriaxone - Bacterial Vaginosis, Vaginal Dysbiosis | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 1794 | 2026-10-01 | 2026-08-27 |
| Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin) - Vaginosis, Bacterial, Bacterial Vaginosis | Phase 2 / Phase 3 | Not yet recruiting | Kaneka Americas Holding Inc. | 160 | 2026-04-01 | 2026-04-14 |
| Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis Boric acid, Placebo - Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital | Phase 3 | Completed | pH-D Feminine Health LLC | 333 | 2025-08-08 | 2026-10-23 |
| Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women 0.20% sodium hyaluronate gel - Vaginismus, Vaginal Atrophy | Phase 3 | Unknown | Biolab Sanus Farmaceutica | 45 | 2025-03-01 | 2024-08-21 |
| Efficacy and Safety of Vaginal Lactobacillus Dual Probiotic Capsules in Bacterial Vaginosis Vaginal Lactobacillus Dual Probiotic Capsules, Placebo - Bacterial Vaginosis (BV) | Phase 3 | Completed | Guangdong Longchuangji Pharmaceutical Co., Ltd. | 402 | 2024-06-12 | 2026-02-18 |
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Effect of PreforPro® on Urinary and Vaginal Health Preforpro, Placebo - Bacterial Vaginosis, Bacterial Infections | Phase 3 | Unknown | Jeremy Burton | 50 | 2024-05-01 | 2024-01-09 |
| Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis Clotrimazole+Lactulose., Canesten (Clotrimazole), Lactulose - Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Recruiting | AVVA Pharmaceuticals Ltd. | 264 | 2024-02-29 | 2025-02-19 |
| Vaginal Hyaluronic Acid, Arginine and Liposome Gel Versus Vaginal Lubricant in Postmenopausal Women With Genitourinary Syndrome of Menopause Vaginal Gel, Vaginal lubricant - Menopause Related Conditions, Atrophic Vaginitis | Phase 2 / Phase 3 | Unknown | Sarawak General Hospital | 52 | 2024-01-01 | 2023-12-28 |
| Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories, Lactulose 300 mg vaginal suppositories, Pimafucin® (natamycin) 100 mg vaginal suppositories - Vulvovaginal Candidiasis, Genital | Phase 3 | Completed | Avva Rus, JSC | 218 | 2022-12-29 | 2024-05-13 |
| The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms Fluconazole, L-Mesitran - Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina | Phase 3 | Recruiting | Maastricht University Medical Center | 252 | 2022-08-22 | 2023-05-17 |
| Role of Oral Lactoferrin in Prevention of Recurnt Bacterial Vaginosis in Pregnancy lactoferrin - Bacterial Vaginosis | Vaginal | Microbiology | Phase 2 / Phase 3 | Unknown | Zagazig University | 66 | 2022-07-01 | 2023-01-03 |
| Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Ibrexafungerp - Vulvovaginal Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 150 | 2022-05-01 | 2024-07-10 |
| A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9 - Human Papillomavirus Infection | Phase 3 | Active not recruiting | Beijing Health Guard Biotechnology, Inc | 2750 | 2022-03-23 | 2022-12-27 |
| Efficacy and Safety of the Application of Local Anaesthetic in Spray to Repair of 1st- 2nd Perineal Lacerations Lidocaine Hydrochloride, Mepivacaine Injection - Vaginal Discharge, Perineum; Rupture | Phase 3 | Completed | Azienda Sanitaria-Universitaria Integrata di Udine | 136 | 2022-01-20 | 2023-09-21 |
| Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection 10% povidone iodine - Cesarean Section Complications, Vaginal Infection | Phase 3 | Unknown | Cairo University | 800 | 2021-09-15 | 2022-07-18 |
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years - HPV Infections, Cervical Cancer Stage IIa | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1348 | 2021-09-15 | 2024-04-17 |
| A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis SHR8008, Fluconazole - Recurrent Vulvovaginal Candidiasis | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 196 | 2021-09-14 | 2021-10-12 |
| Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study Secnidazole 2 GM Oral Granules - Recurrent Bacterial Vaginosis | Phase 2 / Phase 3 | Completed | Indiana University | 24 | 2021-07-09 | 2024-02-05 |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years 9-valent HPV vaccine - HPV Infections, Cervical Cancer | Phase 3 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 1200 | 2021-05-28 | 2024-04-17 |
Showing 20 of 117. Sign in to see all of them.
Vaginosis, Bacterial (40) · Candidiasis, Vulvovaginal (25) · Uterine Cervical Neoplasms (18) · Vaginal Neoplasms (18) · Vaginitis (17) · Vulvar Neoplasms (14) · Atrophic Vaginitis (13) · Condylomata Acuminata (11) · Papillomavirus Infections (10) · Atrophy (6) · Endometrial Neoplasms (5) · Vaginal Discharge (5) · Premature Birth (4) · Trichomonas Vaginitis (4)
Female Urogenital Diseases (117) · Female Urogenital Diseases and Pregnancy Complications (117) · Genital Diseases (117) · Genital Diseases, Female (117) · Urogenital Diseases (116) · Infections (78) · Vaginitis (70) · Bacterial Infections and Mycoses (63) · Vulvar Diseases (40) · Bacterial Infections (39) · Pathological Conditions, Signs and Symptoms (32) · Mycoses (26) · Vulvitis (26) · Candidiasis (24)
Metronidazole (13) · Fluconazole (8) · Dehydroepiandrosterone (7) · Clotrimazole (5) · Ospemifene (5) · ibrexafungerp (5) · astodrimer (4) · Clindamycin (3) · Estradiol (3) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (3) · VT-1161 (3) · Vaginal Creams, Foams, and Jellies (3) · boric acid (3) · secnidazole (3) · terconazole (3)
Merck Sharp & Dohme LLC (7) · EndoCeutics Inc. (6) · Scynexis, Inc. (5) · Shanghai Bovax Biotechnology Co., Ltd. (5) · Shionogi (5) · Starpharma Pty Ltd (4) · Curatek Pharmaceuticals, LLC (3) · Mycovia Pharmaceuticals Inc. (3) · Actavis Inc. (2) · Alliance for Clinical Trials in Oncology (2) · Assiut University (2) · Avva Rus, JSC (2) · Lumara Health, Inc. (2) · Medinova AG (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2)
United States (43) · Canada (10) · China (9) · Russia (6) · Austria (5) · Germany (5) · France (4) · India (4) · Italy (4) · Puerto Rico (4) · Belgium (3) · Brazil (3) · Czechia (3) · Netherlands (3) · Slovakia (3)
David F Archer, MD (3) · Robert J Borgman, Ph.D. (3) · David F Archer, M.D. (2) · Jeremy Paull, PhD (2) · Jeremy Paull, PhD. (2) · Jim Joffrion (2) · Alfred Moffett, M.D. (1) · Amal Mohamed Alanwar, MD (1) · Andrea E Rodriguez, MD, MsC (1) · Ariel I Ruiz, MD, MsC (1) · Arthur Waldbaum, M.D. (1)
PMID 26972555, PMID 25968836, PMID 27422279, PMID 36396498, PMID 25734980, PMID 26291918, PMID 26517756, PMID 26597311, PMID 26634942, PMID 26731686, PMID 29211620, PMID 29269325, PMID 29767739, PMID 36255448, PMID 38319878, PMID 17128343, PMID 17466514, PMID 17666604, PMID 18532873, PMID 18768432, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19424093, PMID 19436225, PMID 19436226, PMID 19616720, PMID 19936044, PMID 20370481, PMID 20459349, PMID 20591191, PMID 20801446, PMID 21216000, PMID 21244215, PMID 21489882, PMID 22059409, PMID 22205034, PMID 22480131, PMID 23361170, PMID 24774442, PMID 25278227, PMID 25511551, PMID 25693011, PMID 25749310, PMID 25771041, PMID 25887336, PMID 25912208, PMID 25912475, PMID 25935783, PMID 25961226
2017 (2), 2008 (1), 2009 (1), 2014 (1), 2023 (1), U10CA180868 (1), UL1TR000135 (1)